Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BBBY when it reaches $0 the fee won't matter.
What still amazes me is the IQ-challenged reddit fam always being more concerned about "the fee" shorts pay as they lose all their money on a bankrupt company with no future. Just like $RDBX and $HMNY it's really amazing.
$CEI I've always preferred "SCAMBER"...nicer ring to it.
How's that "carbon capture" doing the pumpers always pushed? LOL.
$TOPS all Pistiolis new bagholders are bullish imagine that lol.
Greek shipping SCAMS are one notch above Chinese SCAMS.
Now it'll bleed down to about .30 with plenty of pumpers before the next reverse split.
$BBBY some bloodbath and beyond bagholder has 800K shares to dump lol finally realized the common will be worthless.
$BBBY not too bad the new bagholders own $6-$7
$KRBP super close hoping for a multi-bagger here $$
$KRBP FDA [IND] news will blast her sky high the market cap isn't even $4m and $10m financing is already in the bank just a 15.3m share float and they STILL haven't found this gem.
$BBBY bidding up this worthless stock is like a national past time.
Wonder what the carnage will be like when the music finally stops with no bidders.
$FOXO yes after the S-1/A there will be...load $KRBP @ .20 and wait you'll thank me soon only a 3.73 mkt cap and 15m float (AI)
https://kiromic.com/science/technology/
$KRBP not just BioPharma AI BioPharma fighting Cancer...tiny $3.7 market cap when this follow up FDA news comes out which should be any time now stock will explode keep an eye out bb it's dirt cheap right now.
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
Company Reiterates Deltacel is Next Clinical Trial Candidate, with Projected Clinical Trial Launch Expected in Q1 2023
Company is Streamlining Operations to Execute Deltacel-Aligned Development Strategy
HOUSTON, October 06, 2022--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it received validating written feedback on October 4, 2022 from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel™ development strategy.
The purpose of the Pre-IND meeting request was to seek alignment with and to obtain FDA guidance on Kiromic’s proposed development strategy about the chemistry, manufacturing, and controls (CMC), nonclinical studies, and clinical study plan for Deltacel™/KB-GDT for treating subjects with Non-Small Cell Lung Cancer (NSCLC). Kiromic will leverage this FDA Pre-IND written confirmatory feedback and recommendations into a robust IND submission package for a projected clinical trial launch in Q1 2023.
"We are delighted to receive this very productive feedback about Deltacel™/KB-GDT from the FDA, confirming our development strategy for this therapeutic candidate," stated Pietro Bersani, Chief Executive Officer of Kiromic. "It was a strategic decision to focus on metastatic stage 4 lung cancer as our first indication in addressing solid malignancies, and we are very heartened to be continuing to fulfill our mission to address solid malignancies, which represent more than 90% of all cancers."
Further reiterating Management’s focus on executing the Deltacel-aligned development strategy, the Company has streamlined its operations and aligned key resources to advance its Deltacel™ product candidate while maintaining its other product candidates Procel™ and Isocel™. As part of that aligned strategy and following a thorough evaluation to maximize operational efficiencies, Kiromic’s management made the difficult yet necessary decision to eliminate 20 positions or approximately 29% of its workforce. The Company believes these key actions and overall strategy align with financing options it is actively pursuing.
"Deltacel™ is our most advanced therapeutic candidate, and its use of allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cells (GDT) is a next-generation solution for patients. As such, this prioritization also mitigates supply-chain challenges associated with a virus-based approach. We believe these advantages will allow us to efficiently establish the platform’s safety and tolerability and build upon Deltacel™’s previously demonstrated preclinical efficacy across multiple indications. With the FDA guidance in hand, we believe we’ve further strengthened our case to align operations with Deltacel™ and deliver value sooner to our shareholders," commented Bersani.
https://www.businesswire.com/news/home/20221006005406/en/Kiromic-BioPharma-Announces-FDA-Feedback-from-Type-B-Pre-IND-Meeting-Confirms-Deltacel-Development-Strategy
https://kiromic.com/drug-development-pipeline/
Kiromic BioPharma Arranges Up to $10 Million Financing
Litigation with Sabby and Another Institutional Shareholder Settled
October 27, 2022 08:48 AM Eastern Daylight Time
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD, a partnership managed by Yorkville Advisors Global LP, a global investment manager, to sell up to $8 million of the Company’s stock at any time during the 24 months following the date of the SEPA, subject to the effectiveness of a registration statement with the Securities and Exchange Commission and other conditions.
“This equity facility is an important piece of our financing strategy that not only provides flexibility and additional runway towards achieving our clinical milestones, but also enables us to settle a key prior legal issue”
Tweet this
The SEPA gives Kiromic the right, but not the obligation, to sell up to $5 million of shares of common stock, which may be increased by an additional $3 million of shares of common stock, at the Company’s request, subject to terms and limitations set forth in the agreement. The number of shares issuable under the SEPA is limited to a number equivalent to 19.99 % of the outstanding common stock of the Company as of the date of the SEPA agreement unless certain pricing conditions are met, which could have the effect of limiting the total proceeds under the SEPA.
Kiromic separately also secured $2 million in gross proceeds from a new investor through the issuance of a secured convertible promissory note. The convertible note converts into the Company’s common stock at a conversion price equal to $0.35 per share.
Following the close of the two financings, Kiromic also announced the completed settlement of its prior litigation with Sabby Capital Management, another institutional shareholder and certain affiliates.
“This equity facility is an important piece of our financing strategy that not only provides flexibility and additional runway towards achieving our clinical milestones, but also enables us to settle a key prior legal issue,” stated Pietro Bersani, Chief Executive Officer of Kiromic. “We believe Yorkville Advisors will be a strong financial partner for us. With the combination of both financings, we have the facilities in place whereby we have the potential to raise up to $10 million of financing, subject to certain conditions, of which $2 million has already been secured, and we look forward to ongoing discussions with additional potential investors,” continued Mr. Bersani.
For further information on the SEPA or convertible note, including important terms and conditions, please see Company’s filings with the Securities and Exchange Commission, including the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission.
About Kiromic BioPharma
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to detect, develop, and commercialize cell and gene therapies with a therapeutic focus on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid cancers. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.
https://www.businesswire.com/news/home/20221027005642/en/Kiromic-BioPharma-Arranges-Up-to-10-Million-Financing
https://kiromic.com/science/technology/
Yep simply put he knew that pr would jack the price up for the offering he wanted to do and had ready. A true piece of work.
$VERB CEO is a true conniving POS the guy puts out a pr about "fighting naked short sellers" then immediately does a nasty offering the following morning screwing over his shareholders even more. After what he pulled no one except more short sellers will touch his miserable stock with a 100 ft pole.
I really thought I'd seen it all.
$CEI what does Scamber Energy have to do with oil?
Doris pays the bills by diluting to the endless supply of bagholders.
They don't own a drop.
Actually it's not my take is it's this filing which wasn't PR'd and also being an A.I. play:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1812360/000121390023002518/ea171602-8k_foxotech.htm
I missed this one but doesn't matter I like $KRBP better anyways it has just a $15.3M float $FOXO float is 25M.
$KRBP .225 watch this undiscovered A.I. play bb just a 15.3m float:
https://kiromic.com/
$GNS relentless bear trap got them again.
$BBBY good night bankruptcy fam last baggy turn out the lights.
I won't cover until this junk is <$1.
Bed Bath & Beyond Falters in Effort to Find Buyer in Bankruptcy
https://www.bloomberg.com/news/articles/2023-01-27/bed-bath-beyond-falters-in-effort-to-find-buyer-in-bankruptcy
$KRBP could be better than $FOXO when they find it 15.3m float (A.I.)
https://kiromic.com/
$FOXO any catalyst on this or just another P&D?
$BBBY here come the bankruptcy bagholders smashing bids = ZERO
$VERB puny $4M offering with no warrants after doing almost $75M volume today...this is a nice a/h entry.
@ .275
$BBBY bagholders keep adding to their collections in the $4's
Maybe they discover the common will soon be worthless.
$BTB bagholders blindsided by this China scam the $4.50 is 1 share + 1 warrant so $4.50 ÷ 2 = $2.25 but it'll probably be pumped down to around $1.50
CHANGSHA, China, Jan. 18, 2023 /PRNewswire/ -- Bit Brother Limited ("Bit Brother, " "We" or the "Company") (NASDAQ: BTB), announced today that it has entered into a securities purchase agreement with certain accredited investors to sell $7.1 million of its ordinary shares and warrants in a registered direct offering.
Under the terms of the securities purchase agreement, Bit Brother has agreed to sell 1,569,444 ordinary shares and warrants to purchase 2,354,166 ordinary shares. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $4.50. The warrants will expire five years from the date of issuance. The purchase price for one ordinary share and one corresponding warrant will be $4.50. The gross proceeds to Bit Brother are estimated to be $7.1 million before deducting the placement agent fees and other estimated offering expenses.
https://www.prnewswire.com/news-releases/bit-brother-limited-announces-pricing-of-7-1-million-registered-direct-offering-301724783.html
$BBBY Puts printing the meme pumpers don't want to hold a BK company over the long weekend go figure.
$HKD bagholders furiously pumped this scam stock all weekend
$BBBY where's the reddit fam? Big Bags and Bankrupt.
$NVAX testing $11:
Novavax Initiates Phase II Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccines
https://www.genengnews.com/topics/translational-medicine/novavax-initiates-phase-ii-trial-for-covid-19-influenza-combination-and-stand-alone-influenza-vaccines/
$KAL beast? News:
Nordea Investment Management AB Buys New Shares in Kalera Public Limited (NASDAQ:KAL)
Posted by AM Reporter Staff on Jan 4th, 2023
Nordea Investment Management AB purchased a new stake in shares of Kalera Public Limited (NASDAQ:KAL – Get Rating) in the 3rd quarter, HoldingsChannel reports. The firm purchased 311,482 shares of the company’s stock, valued at approximately $383,000.
Several other institutional investors have also added to or reduced their stakes in KAL. UBS Group AG purchased a new stake in Kalera Public during the second quarter valued at about $31,000. JPMorgan Chase & Co. purchased a new stake in Kalera Public during the second quarter valued at about $100,000. Pictet Asset Management SA purchased a new stake in Kalera Public during the second quarter valued at about $169,000. Platinum Investment Management Ltd. purchased a new stake in shares of Kalera Public during the second quarter worth about $2,727,000. Finally, Mak Capital One LLC purchased a new stake in shares of Kalera Public during the second quarter worth about $3,999,000. 15.15% of the stock is currently owned by hedge funds and other institutional investors.
https://reporter.am/2023/01/04/nordea-investment-management-ab-buys-new-shares-in-kalera-public-limited-nasdaqkal.html
$CMMB just the old bagholders dumping onto new ones.
This is a zero of a company with zero catalysts.
$AHPI testing $1.05 now from .89 alert imagine that.
$LHDX 730% blowup bb watch these beaten up Covid penny stocks hope you had a good holiday season $$
$KAL grabbed 919 shares myself I think it goes big tomorrow $RSLS the algos haven't picked it up yet.
$LHDX beast like I said Covid plays just starting
$KAL yep could blow up if it LUDP halts
https://www.globenewswire.com/news-release/2022/12/23/2579190/0/en/Kalera-Shareholders-Approve-Reverse-Stock-Split.html
$NVAX reloaded the sub $10 pullback when market tanked.
$RSLS pos halted up 154% low floaters are going.
$NVAX $INO $AHPI new Covid subvariant spreading like wildfire.
https://www.wbaltv.com/article/with-hospitals-90-capacity-officials-worried-about-covid-19-surge/42383873
$CMMB offering after the bell or AM in 3..2..1...
$NVAX going to roar next week most people took off early and will be chasing all the Covid stocks.
$AHPI already 5X volume imagine what happens over the weekend with COVID there's a new lethal variant called bf.7
https://www.cnn.com/2022/12/30/health/covid-variants-concern-new-year/index.html